. Author manuscript; available in PMC: 2015 Jul 1.

Published in final edited form as: Lancet Neurol. 2014 May 27;13(7):676–685. doi: 10.1016/S1474-4422(14)70088-2

Table 2.

Mean Difference in Change in Outcome Measures from Intent to Treat Analysis

	Median rank, value (95%CI)		Mean difference in values (95%CI)	p value
	Davunetide	Placebo
	n = 151	n = 153
Primary Outcomes
PSPRS	152.5, 11.8 (10.5, 13.0)	152.5, 11.8 (10.5, 13.0)	0 (−2.2, 1.8)	0.41
SEADL	153, −0.20 (−0.20, −0.17)	153, −0.20 (−0.22, −0.17)	0 (−0.02, 0)	0.92
Secondary Outcomes
CGIC	168.5, 6.0 (5.9, 6.1)	168.5, 6.0 (5.5, 6.1)	0 (0, 0)	0.34
MRI Ventricular vol.(× 10⁴ mm³)	121.0, 0.38 (0.33, 0.45)	112.0, 0.38 (0.32, 0.45)	0.005 (−0.07, 0.08)	0.72

N and P values are from full analysis population (Figure 1).Abbreviations: PSPRS: Progressive Supranuclear Palsy Rating Scale; SEADL: Schwaab and England Activities of Daily Living Scale; CGIC: Clinical Global Impression of Change